U.S. markets close in 2 hours 5 minutes
  • S&P 500

    3,251.55
    -58.56 (-1.77%)
     
  • Dow 30

    26,291.08
    -368.03 (-1.38%)
     
  • Nasdaq

    10,869.28
    -316.31 (-2.83%)
     
  • Russell 2000

    1,535.95
    -25.63 (-1.64%)
     
  • Crude Oil

    35.35
    -0.82 (-2.27%)
     
  • Gold

    1,878.40
    +10.40 (+0.56%)
     
  • Silver

    23.61
    +0.25 (+1.07%)
     
  • EUR/USD

    1.1652
    -0.0026 (-0.22%)
     
  • 10-Yr Bond

    0.8550
    +0.0200 (+2.40%)
     
  • GBP/USD

    1.2945
    +0.0022 (+0.17%)
     
  • USD/JPY

    104.6390
    +0.0290 (+0.03%)
     
  • BTC-USD

    13,509.08
    +210.24 (+1.58%)
     
  • CMC Crypto 200

    263.85
    +0.22 (+0.08%)
     
  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Nuvectra® to Participate in Two Upcoming Investor Conferences

PLANO, Texas, June 12, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that members of management are scheduled to participate in two upcoming investor conferences in New York, NY.

Event:

Raymond James 2019 Life Sciences and MedTech Conference

Date:

Tuesday, June 18, 2019

Time:

11:30 a.m. ET

Location:

Lotte New York Palace Hotel

Format:

Presentation & 1x1 Meetings

Event:

JMP Securities Life Sciences Conference

Date:

Wednesday, June 19, 2019

Time:

2:00 p.m. ET

Location:

The St. Regis New York

Format:

Presentation & 1x1 Meetings

Webcasts of the Company’s presentations will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. Webcast replays of the presentations will be available for 90 days.

About Nuvectra Corporation

Nuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. Visit the Nuvectra website at www.nuvectramed.com.

Company Contacts:

Investor Contacts:

Nuvectra Corporation

The Ruth Group

Jennifer Kosharek

Tram Bui

(214) 474-3107

(646) 536-7035

jkosharek@nuvectramed.com

investors@nuvectramed.com